論文

査読有り
2017年9月

DAF-shielded baculovirus-vectored vaccine enhances protection against malaria sporozoite challenge in mice

MALARIA JOURNAL
  • Mitsuhiro Iyori
  • ,
  • Daisuke S. Yamamoto
  • ,
  • Miako Sakaguchi
  • ,
  • Masanori Mizutani
  • ,
  • Sota Ogata
  • ,
  • Hidesato Nishiura
  • ,
  • Takahiko Tamura
  • ,
  • Hiroyuki Matsuoka
  • ,
  • Shigeto Yoshida

16
1
開始ページ
390
終了ページ
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1186/s12936-017-2039-x
出版者・発行元
BIOMED CENTRAL LTD

Background: Previous studies have shown that the baculovirus-vectored vaccine based on the "baculovirus dual expression system (BDES)" is an effective vaccine delivery platform for malaria. However, a point of weakness remaining for use of this vaccine platform in vivo concerns viral inactivation by serum complement. In an effort to achieve complement resistance, the gene encoding the human decay-accelerating factor (hDAF) was incorporated into the BDES malaria vaccine expressing the Plasmodium falciparum circumsporozoite protein (PfCSP).
Results: The newly-developed BDES vaccine, designated BDES-sPfCSP2-Spider, effectively displayed hDAF and PfCSP on the surface of the viral envelope, resulting in complement resistance both in vitro and in vivo. Importantly, upon intramuscular inoculation into mice, the BDES-sPfCSP2-Spider vaccine had a higher protective efficacy (60%) than that of the control vaccine BDES-sPfCSP2-Spier (30%) against challenge with transgenic Plasmodium berghei sporozoites expressing PfCSP.
Conclusion: DAF-shielded BDES-vaccines offer great potential for development as a new malaria vaccine platform against the sporozoite challenge.

Web of Science ® 被引用回数 : 9

リンク情報
DOI
https://doi.org/10.1186/s12936-017-2039-x
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/28962615
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000412212000003&DestApp=WOS_CPL

エクスポート
BibTeX RIS